Superworth

Cardiff Oncology price to sales ratio CRDF

Market value divided by revenue over the last twelve months, since 2013.

Today, Nov 2, 2026
129×
10-year median
86.8×
Against its 10-year history
59th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.1× to 200×
Peer median
1.3×

Cardiff Oncology's price to sales ratio is 129× as of Nov 2, 2026.

That is above its ten-year median of 86.8×, close to the middle of its last ten years.

Over that time it ranged from 7.1× in Jul 2018 to 200× in Aug 2023.

The median for 10 healthcare stocks of a similar size is 1.3×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far129×108×198×
2025n/m a value too high to mean anything
2024171×145×198×
2023144×97.1×200×
2022160×144×181×
2021n/m a value too high to mean anything
2020169×18.4×178×
201923.1×12.1×51.0×
201826.1×7.1×43.8×
201730.4×24.5×187×
2016164×164×195×
2015n/m a value too high to mean anything
2014n/m a value too high to mean anything
2013185×185×198×

Against its peers

Companies in Healthcare nearest Cardiff Oncology's size, closest first, today.

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cardiff Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.